Clinical Trials Logo

Healthy Adult Subjects clinical trials

View clinical trials related to Healthy Adult Subjects.

Filter by:

NCT ID: NCT06107205 Completed - Clinical trials for Healthy Adult Subjects

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

Start date: November 7, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, Randomized, Open-Label, Three-Treatment, Three-Period Crossover Study to Assess Bioequivalence and Safety of TTYP01 Tablets to Radicava® Injection, and Radicava ORS® in Healthy Adult Subjects Under Fasting Conditions.The objective is To characterize the bioequivalence、safety and tolerability of TTYP01 tablets and Radicava® injection or Radicava ORS®in healthy adult subjects under fasted conditions.In this study, 30 healthy adult subjects will receive TTYP01, or Radicava, orRadicava ORS in each period according to the randomization sequence.

NCT ID: NCT06063291 Recruiting - Clinical trials for Healthy Adult Subjects

Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects

Start date: November 20, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of ID110521156 in healthy adult sbujects. This is the first clinical study of ID110521156.

NCT ID: NCT05917782 Completed - Clinical trials for Healthy Adult Subjects

A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects

Start date: July 18, 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, open-label, single-dose, parallel-designed PK similarity study.

NCT ID: NCT05909644 Completed - Clinical trials for Healthy Adult Subjects

An Open-label DDI Study of Omaveloxolone in Healthy Subjects

Start date: July 5, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, single-sequence, 2-period crossover study in healthy subjects. In this study, 20 subjects will be enrolled to allow at least 16 evaluable subjects. Subjects will receive a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) on Day 1 (Period 1) and on Day 29 (Period 2), and 600 mg efavirenz once a day from Days 15 through 42 (Period 2).

NCT ID: NCT05641181 Recruiting - Clinical trials for Healthy Adult Subjects

A Trial of CRB4101 in Healthy Subjects

Start date: November 16, 2022
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is toevaluate the safety and tolerability of a single dose of CRB4101 tablets in healthy adults . The main questions it aims to answer are: - [question 1]The pharmacokinetics (PK) and pharmacodynamic dynamics (PD) characteristics of CRB4101 tablets were evaluated in healthy adults after a single administration. - [question 2]Exploratory analysis of the relationship between serum concentrations of CRB4101 (and its major metabolites, if necessary) and QTc interphase. - [question 3]Exploratory analysis of the metabolic and excretory characteristics of CRB4101 after a single administration (if necessary) - [question 4]Exploratory analysis of pharmacokinetic characteristics of major metabolites of CRB4101 (if necessary) - [question 5]The influence of pharmacogenomics on pharmacokinetic characteristics (if necessary). After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high: 100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg

NCT ID: NCT05632211 Completed - Clinical trials for Healthy Adult Subjects

A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants

Start date: December 16, 2022
Phase: Phase 1
Study type: Interventional

Rationale: Alvotech is developing AVT05 globally as a proposed biosimilar to the reference product Simponi (golimumab) for subcutaneous (SC) use. This is a first-in-human (FIH) clinical study with AVT05. The study aims to demonstrate pharmacokinetic (PK) similarity of the proposed biosimilar test product AVT05 and the reference products EU approved Simponi and US-licensed Simponi, in addition to evaluating the safety and tolerability of AVT05, when administered as a single 50 mg/0.5 mL SC dose.

NCT ID: NCT05342597 Completed - Clinical trials for Healthy Adult Subjects

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)

Start date: June 10, 2019
Phase: Phase 1
Study type: Interventional

To evaluate the effect of food on the pharmacokinetics of oral edaravone in healthy adult subjects. In this study, we determined 5 different dietary conditions including 4 different meal contents and fasting condition.

NCT ID: NCT05334043 Recruiting - Clinical trials for Healthy Adult Subjects

Pharmacokinetics and Bioavailability of Curcumin UP 30 Capsules in Healthy Adult Subjects

CuminUP30
Start date: March 23, 2022
Phase: Phase 1
Study type: Interventional

A single-center, open-label, randomized, two-period, crossover study design of pharmacokinetics and bioavailability in healthy adult male and female subjects under fasting conditions.

NCT ID: NCT05223660 Completed - Pharmacokinetics Clinical Trials

A Phase I Pharmacokinetics Study for KT07 Capsule

Start date: January 7, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1 single-center study to assess the pharmacokinetics (PK), safety and tolerability of KT07 capsules in healthy adult subjects. This study consists of 2 parts: Part 1 and Part 2. The primary objectives of Part 1 include selection of suitable PK markers for bioanalysis, development and validation of GLP bioanalytical methods for follow-up PK studies, assessment of PK of potential markers following an oral administration of KT07, and provision of PK sampling strategy for Part 2. The primary objective of Part 2 is to evaluate the PK profile following a single dose and multiple doses in healthy adult subjects.

NCT ID: NCT05040113 Completed - Clinical trials for Healthy Adult Subjects

A Study On Human Mass Balance And Biotransformation

Start date: September 4, 2021
Phase: Phase 1
Study type: Interventional

This study will evaluate the absorption,metabolism and excretion of CBP-307 in healthy chinese male subjects.